Updates are available Correction dated 2021-03-31
Click to view Correction: https://doi.org/10.1007/s11523-021-00812-7
-
Authors
Patelli, Giorgio
Vaghi, Caterina
Tosi, Federica
Mauri, Gianluca
Amatu, Alessio
Massihnia, Daniela
Ghezzi, Silvia
Bonazzina, Erica
Bencardino, Katia
Cerea, Giulio
Siena, Salvatore
Sartore-Bianchi, Andrea https://orcid.org/0000-0003-0780-0409
-
Funding
Funding for this research was provided by:
Università degli Studi di Milano
- License Information
-
More Information
Article History
Accepted: 1 February 2021
First Online: 18 March 2021
Change Date: 31 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11523-021-00812-7
Declarations
:
: The authors are supported by Fondazione Oncologia Niguarda Onlus.
: Salvatore Siena is an advisory board member for Amgen, Bayer, BMS, CheckmAb, Clovis, Daiichi-Sankyo, Merck, Roche-Genentech, and Seattle Genetics. Andrea Sartore-Bianchi is an advisory board member for Amgen, Bayer, Sanofi, and Servier. Giorgio Patelli, Caterina Vaghi, Federica Tosi, Gianluca Mauri, Alessio Amatu, Daniela Massihnia, Silvia Ghezzi, Erica Bonazzina, Katia Bencardino, and Giulio Cerea have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: GP, CV, FT, and ASB performed the literature search and were major contributors in devising and writing the manuscript. GM, AA, DM, SG, EB, KB, and GC contributed by identifying ongoing trials and provided a critical revision of the draft. ASB and SS provided the concept and design of the review, critical revision of the draft, and final approval of the version to be submitted. All authors read and approved the final manuscript.
: Not applicable.
